Core Viewpoint - The company reported a significant increase in revenue but continued to face net losses, indicating ongoing challenges in the pharmaceutical industry amid regulatory pressures and market competition [4][26]. Financial Performance - The company achieved operating revenue of 37,978.02 million yuan, a year-on-year increase of 92.95% [4][26]. - The net profit attributable to the parent company was -13,076.37 million yuan, a reduction in losses by 13.68% compared to the previous year [4][26]. - The total assets decreased by 22.73% to 125,533.36 million yuan, with a notable decline in both current and non-current assets [26][27]. Industry Context - The pharmaceutical industry is undergoing a transformation, with increasing regulatory scrutiny and a shift towards high-quality development [4][15]. - The government continues to expand centralized procurement policies, which are impacting pricing and competition within the industry [15][16]. - The aging population in China is driving demand for healthcare products and services, presenting opportunities for growth in the pharmaceutical sector [16]. Strategic Initiatives - The company is focusing on enhancing its product pipeline by investing in high-difficulty generics and innovative drugs, aiming to strengthen its competitive edge [5][10]. - A strategic partnership with Laboratoire Bailly-Creat aims to expand the company's market reach, particularly in emerging markets along the Belt and Road Initiative [7][17]. - The company is committed to improving its internal control systems and operational efficiency to adapt to the evolving regulatory landscape [18][19].

灵康药业集团股份有限公司 2024 年年度股东大会会议资料 (603669) 二〇二五年五月 灵康药业集团股份有限公司 2024 年年度股东大会会议资料 灵康药业集团股份有限公司 2024 年年度股东大会会议资料目录 | 2024 年年度股东大会会议议程 | | | 2 | | | --- | --- | --- | --- | --- | | 2024 年年度股东大会会议须知 | | | 4 | | | 议案一：公司 | 2024 | 年度董事会工作报告 | | 5 | | 议案二：公司 | 2024 | 年度监事会工作报告 | | 15 | | 议案三：公司 | 2024 | 年年度报告全文及摘要 | | 17 | | 议案四：公司 | 2024 | 年度财务决算报告 | | 18 | | 议案五：公司 | 2024 | 年度利润分配预案 | | 24 | | 议案六：关于公司及全资子公司向银行申请 | | | 2025 年度综合授信额度及提供相应 | | | 担保事项的议案 | | | | 25 | | 议案七：关于修订《募集资金管理制度》的议案 | | | | 26 | 第 1页 共 26 页 灵康药 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-036 | | --- | --- | --- | | 证券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 关于不向下修正"灵康转债"转股价格的公告 1、因公司实施 2020 年年度利润分配方案，自 2021 年 5 月 31 日起，转股价 格调整为 8.61 元/股，具体内容详见《关于"灵康转债"转股价格调整的提示性 公告》（公告编号：2021-027）。 2、因公司实施 2021 年年度利润分配方案，自 2022 年 7 月 5 日起，转股价 格调整为 8.51 元/股，具体内容详见《关于权益分派引起的"灵康转债"转股价 格调整的公告》（公告编号：2022-042）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 5 月 9 日，灵康药业集团股份有限公司（以下简称"灵康药 业"或"本公司"）股价已出现连续三十个交易日中至少有十五个交易日的收盘 价低于当期转股价格的 85%之情 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-034 灵康药业集团股份有限公司 关于全资子公司获得药物临床试验批准通知书的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、药品基本信息 药品名称：乙酰唑胺缓释胶囊 剂型：缓释胶囊 注册分类：化药 3 类 申请事项：境内生产药品注册临床试验 申请人：海南灵康制药有限公司 灵康药业集团股份有限公司（以下简称"公司"）全资子公司海南灵康制药 有限公司（以下简称"灵康制药"）于近日取得国家药品监督管理局药品审评中 心（CDE）（以下简称"药审中心"）签发的关于乙酰唑胺缓释胶囊的《药物临床 试验批准通知书》，现将相关情况公告如下： 受理号：CYHL2500037 通知书编号：2025LP01211 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 2 月 10 日受理的乙酰唑胺缓释胶囊符合药品注册的有关要求，同意开展临床 试验。申请的适应症：适用于预防或改善逐步上升的情况下仍然会出现的急性高 山病的相关症状。 二、药品研发情况 ...

Group 1 - The company Lingkang Pharmaceutical (603669) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., has received the Clinical Trial Approval Notice for Acetazolamide Sustained-Release Capsules from the National Medical Products Administration [1] - The drug is intended for the prevention or improvement of acute mountain sickness symptoms that may occur under gradually increasing conditions [1] - As of the announcement date, the company has invested 6.9 million RMB in research and development expenses [1] Group 2 - According to IMS data, the sales revenue of Acetazolamide tablets in China is projected to be 4.4352 million RMB in the first half of 2024 [1]

Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or significant omissions [2][3]. Financial Data Summary - The quarterly financial statements for the first quarter of 2025 are unaudited, with the company confirming that there were no profits from mergers under common control for the current and previous periods, both reporting a net profit of 0.00 yuan [6][7]. - The company holds 17,701,793 shares in its repurchase special securities account, representing 2.45% of the total circulating shares [4]. Shareholder Information - The report includes details on the total number of ordinary shareholders and the status of the top ten shareholders, although there were no changes reported in the lending or returning of shares by major shareholders [5].

Financial Performance - The company's revenue for Q1 2025 was ¥50,121,123.94, a decrease of 34.79% compared to ¥76,861,627.55 in the same period last year[4] - The net loss attributable to shareholders was ¥18,621,240.46, compared to a loss of ¥16,041,506.14 in the previous year[4] - The basic and diluted earnings per share were both -¥0.03, compared to -¥0.02 in the same period last year[4] - The company reported a net loss of CNY 12,846,612.80 for Q1 2025, compared to a net loss of CNY 18,000,000 in Q1 2024[19] - The net profit for Q1 2025 was -18,621,240.46 RMB, compared to -16,041,506.14 RMB in Q1 2024, indicating a decline in profitability[20] - The total profit margin for Q1 2025 was -50.0%, compared to -22.3% in Q1 2024, indicating a worsening financial position[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,231,431,435.30, a decrease of 1.90% from ¥1,255,333,587.55 at the end of the previous year[5] - Total assets decreased to CNY 1,231,431,435.30 as of March 31, 2025, from CNY 1,255,333,587.55 as of December 31, 2024[16] - Total liabilities decreased to CNY 480,286,617.26 as of March 31, 2025, from CNY 485,573,776.61 as of December 31, 2024[16] - The company’s inventory as of March 31, 2025, was CNY 23,300,966.11, down from CNY 27,879,613.88 as of December 31, 2024[15] - The company’s long-term equity investments decreased to CNY 14,584,608.81 as of March 31, 2025, from CNY 17,939,111.32 as of December 31, 2024[15] - The company’s total current assets were CNY 574,661,138.37 as of March 31, 2025, a decrease from CNY 586,610,563.80 as of December 31, 2024[15] Cash Flow - The net cash flow from operating activities was -¥13,569,961.60, an improvement from -¥20,674,871.45 in the previous year[4] - Operating cash flow for Q1 2025 was -13,569,961.60 RMB, an improvement from -20,674,871.45 RMB in Q1 2024[23] - The company had a net cash flow from financing activities of 2,008,404.39 RMB in Q1 2025, compared to -90,043,486.29 RMB in Q1 2024[24] - The company reported a total cash inflow from investment activities of 17,493,263.17 RMB in Q1 2025, compared to 87,327,929.61 RMB in Q1 2024[24] - Cash and cash equivalents as of March 31, 2025, were CNY 256,883,646.75, slightly up from CNY 254,087,208.94 as of December 31, 2024[14] - Total cash and cash equivalents at the end of Q1 2025 increased to 252,657,628.92 RMB from 282,930,347.78 RMB at the end of Q1 2024[24] Revenue and Operating Costs - The decline in revenue was primarily due to the impact of drug collection and price linkage policies, leading to continuous price declines and fluctuations in sales due to seasonal disease outbreaks[8] - Total operating costs for Q1 2025 were CNY 62,962,253.24, down 33.6% from CNY 94,759,740.05 in Q1 2024[19] - Operating income for Q1 2025 was CNY 50,121,123.94, while operating costs were CNY 36,073,102.81, resulting in a gross profit margin of approximately 28.1%[19] - Revenue from sales of goods and services in Q1 2025 was 37,359,969.68 RMB, down from 71,723,378.82 RMB in Q1 2024, reflecting a significant decrease[23] - The total operating expenses in Q1 2025 were 51,456,223.26 RMB, down from 102,528,017.32 RMB in Q1 2024[23] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 20,516, with the largest shareholder holding 47.09% of the shares[10] - The company repurchased 17,701,793 shares, representing 2.45% of the total shares outstanding[11] Government Support - The company received government subsidies amounting to ¥320,303.40 during the reporting period[6] Other Information - The weighted average return on net assets was -2.45%, down from -1.74% in the previous year[5] - The company did not report any net profit from subsidiaries prior to the merger in the current or previous period[21]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0300 | -0.0200 | -50 | -0.0300 | | 每股净资产（元） | 0.96 | 1.14 | -15.79 | 1.41 | | 每股公积金(元) | 0.36 | 0.35 | 2.86 | 0.35 | | 每股未分配利润(元) | -0.45 | -0.27 | -66.67 | -0.07 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.5 | 0.77 | -35.06 | 0.73 | | 净利润(亿元) | -0.19 | -0.16 | -18.75 | -0.23 | | 净资产收益率(%) | -2.45 | -1.74 | -40.8 | -2.05 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 45204.09万股，累计占流 ...

Market Overview - The Shanghai Composite Index closed at 3297.29 points, above the five-day moving average, with a slight increase of 0.03% [1] - The total trading volume of A-shares reached 1,138.919 billion yuan [1] Stocks Performance - A total of 271 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Jinkai Biological (金凯生科) with a deviation rate of 13.09% and a daily increase of 20.02% [1] - Lusi Co., Ltd. (路斯股份) with a deviation rate of 8.64% and a daily increase of 14.74% [1] - Ketaobiotechnology (科拓生物) with a deviation rate of 8.31% and a daily increase of 11.58% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Daychen Co., Ltd. (日辰股份) [1] - YTO Express (圆通速递) [1] - Jiama Clothing (嘉曼服饰) [1]

Core Viewpoint - The A-share market experienced a narrow fluctuation with certain sectors such as electricity, CXO, and vitamins showing strength despite overall market weakness [2][3]. A-share Market Performance - The A-share market showed a slight decline with the Shanghai Composite Index down by 0.1%, Shenzhen Component down by 0.66%, North Star 50 Index down by 2.8%, and ChiNext Index down by 0.68% [3]. - Key performing sectors included daily chemicals, coal, paper, and agriculture, while software services, internet, mineral products, and IT equipment sectors faced declines [3]. Sector Highlights Electricity Sector - The electricity sector saw significant gains with multiple stocks hitting the daily limit up, including Huayin Power (600744) up by 10% to 3.85, Xichang Power (600505) up by 9.97% to 17.31, and Chenzhou International (600969) up by 9.95% to 8.07 [4]. - Other notable performers included Shaoneng Co. (000601) up by 9.93% and Guangxi Energy (600310) up by 8.24% [4]. CXO Sector - The CXO sector exhibited strong performance with Jin Kai Biotechnology (301509) hitting the daily limit up, and Hehua Co. (000953), Kailaiying A-shares, and Lingkang Pharmaceutical (603669) also reaching the limit up [5]. - Kailaiying's Hong Kong shares surged by over 19% during the session [5]. Vitamin Sector - The vitamin concept sector showed notable strength, contributing to the overall positive performance of the market [4]. New Stock Listings - Two new stocks were listed in the A-share market, both experiencing significant increases [9]. - Jiangshun Technology (001400) saw a peak increase of over 120% during trading, focusing on aluminum profile extrusion molds and related equipment [10]. - Tianyouwei (603202) also performed well, with a peak increase nearing 50%, specializing in automotive instrument development and production [11]. Hong Kong Market Performance - The Hong Kong market experienced a decline, with the Hang Seng Index dropping over 1% [12][13]. - Notable declines were observed in major stocks such as Meituan-W and JD.com [13]. - However, New Oriental-S saw a rise of over 6% following the release of its financial results for the third quarter of the 2025 fiscal year, reporting a slight decrease in net revenue but an increase in operating profit [14].